AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Drug-resistant epilepsy (DRE) affects more than 20 million people worldwide. DRE patients do not respond to anti-seizure medications. Shifting from anti-seizure to anti-epileptic and disease-modifying therapy will be an important aim for future research. The canonical nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in epilepsy and neuroinflammation. However, the expression and regulation of RelB, which can be activated via both canonical and non-canonical NF-κB signaling, are obscure in epilepsy. To clarify the expression and localization of RelB in the DRE phenotype and to determine the proteins related to RelB regulation, we conducted the following studies.
Quantitative PCR was performed to detect the transcription of RELB in pilocarpine-induced epileptic rats. Western blotting was used to determine the abundance of RelB and proteins related to RelB regulation in brain tissue from both epilepsy model rats and DRE patients and in liposaccharide-induced HT22 cells. Immunofluorescence staining and immunohistochemistry were used to locate RelB in brain sections from DRE patients. ELISA was used to determine inflammatory cytokines secreted by HT22 cells into the culture medium.
RELB transcription and expression were increased in the hippocampus and cortex of epileptic rats during the acute and latent phases and in epileptic foci of patients with temporal lobe epilepsy. Additionally, RelB levels were mainly increased in epileptic rat neurons and accumulated in the nuclei of hippocampal neurons. Further research demonstrated increased GSK3β phosphorylation at the Ser9 inhibitory site and decreased IκBα levels, which contributed to RelB accumulation in hippocampal neurons after seizure and in liposaccharide-stimulated HT22 cells.
This study is the first to demonstrate that RelB is widely distributed and increased in epileptogenic foci neurons in epileptic phenotypes. These results indicate that RelB may play roles in DRE and is mediated by GSK3β and IκBα, providing a new target for anti-epileptic and disease-modifying therapy.
Spiciarich MC, von Gaudecker JR, Jurasek L, et al. Global health and epilepsy: update and future directions. Curr Neurol Neurosci Rep. 2019;19(6):30.
Sultana B, Panzini MA, Veilleux Carpentier A, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805–817.
Vergonjeanne M, Auditeau E, Erazo D, et al. Epidemiology of epilepsy in low- and middle-income countries: experience of a standardized questionnaire over the past two decades. Neuroepidemiology. 2021;55(5):369–380.
French JA, Bebin M, Dichter MA, et al. Antiepileptogenesis and disease modification: clinical and regulatory issues. Epilepsia Open. 2021;6(3):483–492.
Paudel YN, Semple BD, Jones NC, et al. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches. J Neurochem. 2019;151(5):542–557.
Kwon YS, Pineda E, Auvin S, et al. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation. 2013;10:30.
Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018;15(1):144.
Cai MT, Lin WH. The function of NF-kappa B during epilepsy, a potential therapeutic target. Front Neurosci. 2022;16:851394.
Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034.
Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227–241.
Engelmann C, Riemann M, Carlstedt S, et al. Identification of undescribed Relb expression domains in the murine brain by new Relb: cre-katushka reporter mice. Dev Dyn. 2020;249(8):983–997.
Cildir G, Low KC, Tergaonkar V. Noncanonical NF-κB signaling in health and disease. Trends Mol Med. 2016;22(5):414–429.
Singh S, Singh TG. Role of nuclear factor kappa B (NF-κB) signalling in neurodegenerative diseases: an mechanistic approach. Curr Neuropharmacol. 2020;18(10):918–935.
Lanzillotta A, Sarnico I, Ingrassia R, et al. The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis. 2010;1(11):e96.
Scorza CA, Marques MJG, Gomes da Silva S, et al. Status epilepticus does not induce acute brain inflammatory response in the Amazon rodent Proechimys, an animal model resistant to epileptogenesis. Neurosci Lett. 2018;668:169–173.
Kovacs Z, Czurk o A, K ekesi KA, et al. Intracerebroventricularly administered lipopolysaccharide enhances spike-wave discharges in freely moving WAG/Rij rats. Brain Res Bull. 2011;85(6):410–416.
Listwak SJ, Rathore P, Herkenham M. Minimal NF-κB activity in neurons. Neuroscience. 2013;250:282–299.
Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203–234.
Yilmaz ZB, Weih DS, Sivakumar V, et al. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J. 2003;22(1):121–130.
Moorthy AK, Huang DB, Wang VY, et al. X-ray structure of a NF-kappaB p50/RelB/DNA complex reveals assembly of multiple dimers on tandem kappaB sites. J Mol Biol. 2007;373(3):723–734.
Millet P, McCall C, Yoza B. RelB: an outlier in leukocyte biology. J Leukoc Biol. 2013;94(5):941–951.
Mockenhaupt K, Gonsiewski A, Kordula T. RelB and neuroinflammation. Cells. 2021;10(7):1609.
Mitra S, Ghosh N, Sinha P, et al. Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treatment. Neurosci Lett. 2016;616:86–92.
Riphagen JM, Ramakers IHGM, Freeze WM, et al. Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology. Neurobiol Aging. 2020;85:96–103.
Zhao XR, Zhang YJ, Strong R, et al. Distinct patterns of intracerebral hemorrhage-induced alterations in NF-kappaB subunit, iNOS, and COX-2 expression. J Neurochem. 2007;101(3):652–663.
Waters MR, Gupta AS, Mockenhaupt K, et al. RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme. Oncogenesis. 2019;8(6):37.
Racine R, Okujava V, Chipashvili S. Modification of seizure activity by electrical stimulation. 3. Mechanisms. Electroencephalogr Clin Neurophysiol. 1972;32(3):295–299.
Neumann M, Klar S, Wilisch-Neumann A, et al. Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation. Oncogene. 2011;30(21):2485–2492.
Liang WJ, Yang HW, Liu HN, et al. HMGB1 upregulates NF-kB by inhibiting IKB-α and associates with diabetic retinopathy. Life Sci. 2020;241:117146.
Bhardwaj R, Yester JW, Singh SK, et al. RelB/p50 complexes regulate cytokine-induced YKL-40 expression. J Immunol. 2015;194(6):2862–2870.
Bren GD, Solan NJ, Miyoshi H, et al. Transcription of the RelB gene is regulated by NF-kappaB. Oncogene. 2001;20(53):7722–7733.
Gupta AS, Waters MR, Biswas DD, et al. RelB controls adaptive responses of astrocytes during sterile inflammation. Glia. 2019;67(8):1449–1461.
Schaafsma W, Zhang X, van Zomeren KC, et al. Long-lasting pro-inflammatory suppression of microglia by LPS-preconditioning is mediated by RelB-dependent epigenetic silencing. Brain Behav Immun. 2015;48:205–221.
Murphy CE, Walker AK, O'Donnell M, et al. Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases. Transl Psychiatry. 2022;12(1):21.
Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007;64(15):1930–1944.
Liu X, Ou S, Yin MJ, et al. N-methyl-D-aspartate receptors mediate epilepsy-induced axonal impairment and tau phosphorylation via activating glycogen synthase kinase-3β and cyclin-dependent kinase 5. Discov Med. 2017;23(127):221–234.
Talos DM, Jacobs LM, Gourmaud S, et al. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy. Ann Neurol. 2018;83(2):311–327.
Campa VM, Baltziskueta E, Bengoa-Vergniory N, et al. A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer. Oncotarget. 2014;5(18):8173–8187.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
京公网安备11010802044758号